Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide for Children with Autism Spectrum Disorder
ChiCTR-IPR-16009627Phase 4Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Bumetanide with Placebo (2 arms). Primary endpoint: Children Autism Rating Scale (CARS) score. Planned start Oct 2016; status: not yet recruiting.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ChiCTR-IPR-16009627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009627.